NVCR - Earnings call transcript Q4 2017

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Novocure fourth quarter 2017 earnings results conference call. At this time, all participants are in a listen-only mode. Later, there will be a question-and-answer session and instructions will follow at that time. [Operator Instructions].

As a reminder, this conference call is being recorded. to of conference Finance like Cordova, to now President Vice and would turn over the Ashley I Investor Relations. begin. may you Ma'am,

Ashley Cordova

link Good Eilon be Groenhuysen; by I'm you Novocure's thank on our Head CEO, and Executive morning, Development, us our the Doyle; Kirson. Chief the the viewed everyone, clicking our review CFO, Science Research Danziger; to presented and Wilco Chairman, in for Bill can fourth-quarter The quarter of our today today our fourth joined www.novocure.com joining on website, on performance. Asaf located page. by and our XXXX financial and for XXXX slides Investor results Relations section Events Officer

risks and statement, our and uncertainties, described to this forward-looking of in a we required which our will to include are risks publicly from results not call actual these beyond some law. including discussions involve during from Before by of would statements. as you I in forward-looking start, those SEC statements conference any do filings. number differ and like could materially update time to intend statements projected These We that uncertainties except time remind our those control,

December to With XX-K and and earlier released that, XXXX We that release I ended the of to will months are morning. will our three press will remind available both now our Doyle. our financials prepared first XX, I call make turn a which brief year this over remarks and everyone move in then question-and-answer session. really, Bill for will were the

William Doyle

And good morning, Ashley. Thank everyone. you,

technology, start call global summary a investment quick Novocure significant of new platform with like a For a those to story, with growing commercial our and I'd of upside company proprietary business is today's potential. opportunity. a Novocure's to oncology are who you

for building articulated clearly long-term We have value. a strategy

driving commercial the treatment GBM. of for we're First, Optune adoption of

platform, cancers, tumor fields of inhibiting Treating and Treating Treating is cancer the believe specific pipeline to uses in our patients. frequencies work a Tumor in to anti-mitotic die. advancing proprietary solid are causing a to Fields clinical we that growth can clinical our which therapy date, Second, preclinical Tumor range and In help cell cancer has to we of effect. Fields, work all disrupt shown our a Tumor effective cells Fields tumor consistent cell electric division,

We newly-diagnosed in and have GBM, different cancer Phase survival in unprecedented results preclinical in pilot cancer and lung cancer, cancer II promising lines. data data XX pancreatic five-year ovarian cell

been of known radiation with morning's shown additive while that certain and later exhibiting future Fields other Asaf We synergistic believe but, I'll therapy with side-by-side Treating this the side a ask agents, regarding effect Tumor fourth Treating be XXXX. to Fields cancer profile. first, or surgery, Tumor modalities in I'll and has quarter fit anti-cancer no comments Importantly, progress systemic will potential our toxicity some review to our make treatment the pharmacology. call, during mild

Asaf?

Asaf Danziger

patient growth XXXX, QX fourth our of active $XX.X the growing presentation XX% year revenue record consecutive on Thanks, since therapy more XX X,XXX of Phase year-end, year-over-year patients X% million Bill. quarter quarter data. than our XXXX We III quarter-over-quarter. at initial and in of was XXth pivotal the delivered of With

prescription proud XXXX. fourth shift year, million to active patient year-over-year. full were We XX% we GBM of growth should for in saw revenues, the the notable XXXX. of continue with towards of GBM. prescription patients representing quarter our growth mix growth in net move I'm in outpace quarters. allow to written future the This For newly-diagnosed newly-diagnosed prescriptions during we XXX% delivered progress $XXX in made

of the markets. active estimate For global XXXX, penetration in currently we XX% rate QX our

GBM. newly-diagnosed our of priority to of awareness data generate market unprecedented any commercial and first in Optune is five-year on Our survival

treat we of focused had our As States Neuro-oncologists with centers on neurosurgeons closely in our to and including which Optune high oncologists our as and US patients and fourth about physician QX for physician's XXXX, XX% and confidence support a We increasing XX, awareness should wrote percentage Optune GBM. and We believe standard commercial and fastest than with key represented certified that segment established, our XXX our the a which two in XXX achieved the of treatment Germany among and approximately and and use Optune. remain who GBM. shift believe of milestones the the messaging prescriptions. XX% Radiation customer of Once neurosurgeons QX physician neuro-oncologists in of survival prescription. achieved quarter developing centers certified confidence oncologists of United of strength GBM. largest EMEA. radiation XXXX, more recommendation who certified We second oncologists is December long-term treat are believing Optune. we priorities of among have medical therapy correlates We the centers who awareness growing in start increase globally, levels X,XXX awareness in for

presented for five-year than a analysis alone. showed response with Increase of XX.X% Optune Optune. dose a survival time of XX Patients GBM to patients. predicted patients survival in compliance year post-op use Optune temozolomide X% overall XX% clear to trial data we treated a had rate First, from of who increased more compared that in the November

JAMA publication XX of the our in increase published the final III Second, analysis trial will five-year We Phase trial of unprecedented pivotal in community. of believe within survival our feasibility JAMA peer-reviewed the the year results December. medical our

in Germany, to build certify With therapy. largest and to will of for that, our in continue patients to and national reimbursement to received the Bill XXX December call commercial the had We to Ahead the Japan towards back working GBM R&D. growing of Japan. review Japan to Optune begun began the put decision for turn extended we in XX, received centers Japan our treatment December progress public infrastructure we we date. of to in also I newly-diagnosed XXXX, in have In market reimbursement, the addition which adoption In on Japan is centers plan the and certified reimbursement in to we XXXX. in US to have as XXXX. commercial market

William Doyle

Thank you, Asaf.

In in continued and to increases significant our the congresses. available R&D have during commercial to and data our our publication addition to Fields quarter, advances investments of led fourth Treating progress at in meaningful presentation the scientific understanding Tumor in for

included Fields to we we earlier a cancer Tumor the be potentiates published This glioma in effects at and delays oncology among paradigm. damage and SNO XX Treating of radiation was on Meeting Neuro-Oncology abstracts in which presence by December, Fields Treating demonstrating our presentations, therapy number be lead record throughout interest treatment Our at of our the in the radiation world. an Tumor abstract Tumor therapy Novocure's author. DNA For external of antineoplastic that the belief growing radiation November in This In had tumor of Treating repair treatment Fields and XX Society Annual that cells. believe researchers pathway research strengthens which describes demonstrates what following a preclinical research used treatment an should clinicians

additional potential to solid advance significant Speaking for continue Novocure five clinical we GBM, in market and pipeline our directly needs high beyond opportunities. unmet tumor the indications with to

the are patient PANOVA pivotal both GBM. non-small make believe cell a trial. clinical than opportunities these approval will patients Pancreatic X Tumor in are metastatic leading longer doubled Treating larger pancreatic locally both trial, patients in we each have with X cell lung XXXX. of survival Phase Treating our than diagnosed rate with all cancer of In third incidence death Fields they from tumors plus indications treatment US FDA in a front-line survival nab-paclitaxel desperately to with locally-advanced cause trials the advanced pancreatic compared cancer Treating can III addition the times resectable Tumor cancer received treatment metastases in that third growing Phase XX unresectable, in Tumor we needed our was cancer. In when controls. impact in advanced trial nab-paclitaxel gemcitabine one-year real to the are with Fields the Nearly progression-free survival Fields patients and improve outcomes. pancreatic the PANOVA gemcitabine historical outcomes of III II for non-small no advances December, as IDE and in initiate and and more disease, comprise to enrolling and our advanced cancer brain cancer. and study are cancer, We We locally market of Phase lung and

boards With the are possible. enroll in approval and trial quickly open closely we review to institutional and site patients with as IDE FDA as sites working hand,

trial studies. in is in Our very patients approximately prognosis relatively incidence median We other is cancer asbestos the low last the still survival months is the mesothelioma, in United in data parts with growing. Thankfully, States, patient world, cancer in humanitarian reported incidence use next overall of readout be enrolled XX registration associated pilot although a Phase this our with of clinical exposure. in the There's apply which and we treatment patient XXXX, opens pilot anticipate we data. final of March mid-XXXX. following trial to XX-month mesothelioma, will for mesothelioma the The poor a Earlier most lung Tumor possibility minimum the use a collection the up pleural received Fields in data of device based strong enrollment mesothelioma, II in for XXXX. STELLAR designation the on for Treating II Phase last follow-up the in for

With summary, call I for with consistent review Wilco combination market pleural Tumor standard-of-care application interim data would STELLAR Assuming we in treatment as And from to Fields HDE Treating the HDE an approved approval the our hand anticipate STELLAR clinical us is data. States. chemotherapy analysis, mesothelioma will that to a trial in over for the readout mesothelioma to in now filing United financials. with with our final our allow the

Wilco Groenhuysen

And Thank fourth you, quarter-over-quarter. of of X% million revenue the quarter growing everyone. XX% We year-over-year delivered Bill. record in good and $XX.X XXXX, morning,

by rates policies we of recognition billings. million global revenues, was XX% States the year, be patient $XXX year-over-year. in revenues reimbursement full in we driven by an the per was patient. increase both representing patient coverage increase XXXX, of net increased Optune revenues implementation Revenue and approximately United growth improving driven approval new gross primarily in revenues delivered XXX% XXX per The in per In will positive growth standard, the revenue For net Germany. net with by adoption in the that in ASC increase net and an estimate

the active per States, update everyone positive for call any to We dialogues eager discussions revenues is reimbursement in be from the patient. on United improvement and discussions. an expect net are will that recognize in drive resulting Germany, We these government payers trigger decision in significant Israel with Switzerland and engaged on likely that a next anybody the Medicare

understand billing the the its code for active with for after a for coverage to The focuses reimbursement to not intend Optune we engage a request CMS ensuring predict to in appropriately regarding Medicare discussions currently continue and Optune. plan we're defined Medicare to resolution. to discussion clearly We this administration the Medicare prices under on process and will Medicare rules. timeline discussions Optune We existing when Medicare unable for have calculate come how does pricing. CMS

treat payments same reduce in from and Medicare. XX% driven revenues, reminder, improved we of a XX% as gross XX% initiatives have ongoing revenues revenues to and As the $XX $XX.X of improved or revenues XX% our scale. although population, last the received million was efficiency to patient margin quarter we was of to by net Gross efforts Medicare of compared profit to with quarter patients, net material not The billings the US year. the yet percentage for million representing cost a by or net continue both any of

patients III quarter statement, expenses of were R&D to future in the increase expenses we same pivotal last income trials. the $X.X We the XXXX our period fourth Phase quarters to $XX that continue enroll million R&D down year. as million Moving compared anticipate for will for in

are and our funding advance tumor value our clinical development full indications. activities realize research committed technology We pipeline of the across and to solid multiple

million $XX.X same for the $XX.X period last Our were the year. quarter SG&A compared million to for expenses

million in in $XXX.X XXXX the of XX% growth XXXX. see with For in ours and objective operating we for in were these revenue continue strategic leverage only to the million versus commercial This efforts. expenses SG&A represents in growth a XXXX, same business $XXX.X results Driving to in of has XXXX our the SG&A XXXX expenses. full XXX% year been period core compared

to $XX.X for was per Our loss last loss same quarter period share was XXXX share-based last to net operating quarter $XX.X non-cash a $X.XX for compared $X.X loss the compared $X.X to per that for loss million $X.XX to compensation million important year. the XXXX employees. our fourth operating XXXX year. million or fourth million loss operating fourth note or $XX.X quarter Net the million an period same in of share of includes It's

focus on reduction investments had At on in XXXX, in total million and short-term year-over-year XXst, our existing cash, cash ongoing resulted Our significant we infrastructure of our burn. has in leveraging equivalents sheet. balance a $XXX.X cash December

business GBM XX:XX] [indiscernible our Importantly, pipeline.

are by we fund and were improved will loans Phase when continue funding debt research which financial increase February million activities transaction, covenants, capital. as of investment new managed clinical loan. used pay We In are expenses a the to explicit pipeline funds so Proceeds existing term in enroll III $XXX trials. us advance maturity and with Advisors, now these committed fund no patients quarters to cash XXXX, our this the agreement to further extends we anticipate XXXX. the There we during of LP. and profile to this to debt our million into development of an full in be significantly loan in Through future February position Novocure's $XXX strengthened will available we loan Pharmakon term term working entered to our to term the

not company non-diluted will a with the the reduces credit needed unimportantly, demonstrating continue technology, Novocure provides new strong proprietary upside the reduced significantly that capital capital, core be we We stability fund business us and and agreement We're a a potential. growing oncology additional this a to clear support to but believe our commitment two commercial is platform financial to global strategies cost the of flexibility a our focused significant Lastly, sheet. our to The with on company. facility balance execute risk of with priorities. capital.

First, drive commercial adoption of Optune.

clinical I'll XXXX open where Tumor include our we enter range well-positioned the advance both patients. a call fronts. think questions. to to execute We solid we to tumor Fields of can that, help Second, pipeline believe Treating Operator? cancers on With

Operator

[Operator Instructions]. you. Thank

Our comes first Deutsche Bank. from Gilbert Gregg with question

You may begin.

Gregg Gilbert

Thank you, a have few. team. I

and since year you you year First, this Japan there's the help R&D expenses, penetration, and SG&A Wilco, through can for And quarters? been phase the operating the may the end can given how talk any if us with talk about approval about there? the of

Wilco Groenhuysen

Good Gregg. morning,

start one, penetration, the opportunity. we're excited Let's because with very second Japan about that

goes then organizing approval hospitals received in for terms you the December We of chain patients of in on the through there As process putting XXXX know, with we because hospitals reimbursement. started ourselves treatment. and contracting supply

steps prior payments one the you'll As recall to treatment actually in prior from centers on certified and patients JSNO the calls, from [ph] XXX We we already first payments made had of strong recruited in significant decision. received first initial – January. we support and We reimbursement Japan. those

prepared expenses, Japan. So, With said we're where are very with in operating I pleased to in respect I it the we think remarks.

but Our we full SG&A year, for about increased the doubled revenue. by XX% our

one operating of in as leverage will you totally core we our our committed As succeeding to recall, are improving objectives.

commercializing not GBM significantly. clinical has changed and running are clearly two pipeline effectively. other our That The of

operating little be our We said, will enrolling. trials that we to I now to committed with the enrollment But go leverage. continue bit expect that III of up Phase as expenses R&D do we're a improving

Gregg Gilbert

agreement to then, And How are two I assume Phase And come all? what share studies? think looks that to in if could. commercial on some quick ones, Can if on when would affect business, you've I at ongoing interim we just should for III Medicare, you your the there pricing about pricing. degree

Wilco Groenhuysen

Yeah.

it's the discussion a this? pricing net protocol focusing ultimately Bill, that what to words We're since is fixed is to very what talk know call no Maybe very to land, part we revenue I improve question. on is focused the revenue that on is We CMS. pricing. Medicare, that. is will fortunate. first or we a the significantly. the it believe one from for tried or And the we that. be take gross where but think there don't It's XX% Eilon on available of on ultimately on the about will Let's the that is explain could where you, There price difficult predict second. parameters He'll call. mechanism We're the few of the timeline

William Doyle

focused the between we patients the for consistently and which are Medicare one XX% of you'll we It's to Again, hand, Sure. of XX% our XX% on receive prescriptions. all as The continue treat business. US of recall represented XX% our mentioned, now US business. and Wilco pricing. discussions,

CMS at levels them highest in the of Washington. conducting are We

having the not discussions we're So, the remote at site.

the We the groups. that timeline, as constructive if brain there's Hill, continue we advocacy discussions of feel a It's variety as both point. Capitol the this benefit to as but on support among not tumor from at extremely well of sides whole significant frustrating aisle are

Gregg Gilbert

get sorry we question affect to whatever commercial expect just pricing Before I was more business? The your existing interject. have about to pricing, you I'm question, the to Thanks. would pipeline in is, the it

William Doyle

Right we do now, not.

Gregg Gilbert

you. Thank

Asaf Danziger

Okay.

Regarding after metastases interim The so, Treating interim it PANOVA other where plan. analyses an do with III stereotactic have of we're the trial have METIS Fields, treating patients the Phase radiosurgery studies, two not X analyses, LUNAR plant. studies, and brain all, first Tumor analysis interim does

analyses. disclose the timing However, we of don't those exact

Gregg Gilbert

guys. Thanks,

Operator

Thank you.

Our with question comes Fargo. from next Wells Biegelsen Larry

begin. may You

Larry Biegelsen

taking Good morning. the Thanks question. for

wanted on first trends the GBM. in start So, to I

significantly by trending because diagnosed And model. ask QX. was of had important you about where I'm couple on and in you therapy XX% asking those those follow-ups. wanted are patients a I drivers to said. see significantly globally, I our And our duration by about It just of XXXX. guess, newly year-over-year therapy, XX% increased of So, percent in the up math, was – it the pretty about in of I

William Doyle

Larry, good morning.

we know, guide. As you don't

of patients with patients benefits are diagnosis till so waiting than they time the clinicians, recurrence. work has of consistent to focus treated to been organization our when it from that a understand However, the rather commercial

weight. of We will year. think choose patients various the start And at majority should not get are significant noted, Optune that patients, movement certainly and, over the enter will fact, the We for may may pushing to of that we or to diagnosis. clinical you XXX% that But course contain ever vast to trials believe reasons, saw of the don't because time may trend. in majority, they as continue continue other last the to quite we

Larry Biegelsen

the I wanted And ask well. as prescription about to growth

diagnosed you so growth versus the past the we driving we've growth to hear Asaf's to been shift I comments you the clearly versus is what recurrent, disconnect – quarters. which between follow-up. faster But don't in QX did and US diagnosed was expect shift prescriptions up, seen past prescriptions. some in don't in have But I XX% prescriptions in working. don't hoping XXXX? US in and three quarters? year-over-year over strategic prescriptions if – consensus, for on newly newly the the what I about XX% I Would patients I three prescriptions been in have strategy your sequentially growing guys one They've I therapy. you in the guide, has on from flat So, And and focus know but in think, a have so, that that understand set to that's was more drives relatively US XXXX XXXX, you could prescription I QX US. did than And in expectations hoping the

Asaf Danziger

the guiding in you we other means increase to increase said, whether treatment, you markets. we patient well. on to And continue that expect as So, expect on prescription US patient order in – need increase continue we grow the to to penetration and continue as are not which – treatment, to we're to to

Larry Biegelsen

– maybe median mesothelioma, plan need And my questions. on enough. you is the question to to and do be survival? successful on taking on for thoughts fair basically What do where some overall think Okay, data you Thanks the show preliminary commercially? then, when disclosing you just

Asaf Danziger

answer happy be I'll Sure. to that.

expect what expecting we've attempt for and collecting to data following consistent seen have trial the to that for trial have the with data data. mid-XXXX mesothelioma. past, we to of get authorities on from STELLAR the is all, should the in be If So, enough us all first we're approval the as submit period follow-up of to regulatory said, the to

enable have which to we exemption designation path a that, get use As submit opens you to in remember, mesothelioma, in HDE, actually us for humanitarian mesothelioma. device If the that an commercialize we humanitarian US. the would

Larry Biegelsen

think on and XX show me overall no to Okay. comment you'd That's showed drop. the But survival what for original think Thanks. it because you median survival overall need I median the I'll you don't in patients?

Asaf Danziger

Thank you.

Operator

Thank you.

comes Securities. question with next from Our Difei Mizuho Yang

You begin. may

Difei Yang

you morning. my questions. Good for taking Thank

XXs one. down XX%. going talk you think, about Wilco, So, could you on? there? gross guided, from is what going on in the might going a net just dynamics quick to to that, upper slightly What involved I be What's

Wilco Groenhuysen

thanks the And question. morning. Good for

certain under quarters, As What I accrual-based the that, quarter from accounting revenue basis, this recognition after of we it cash-based cash-based the net, in favorably third rec. was was bump impacted receivables at – rev to certain that estimated we the patient-payer third to moved in of rev relationship to were XX%, And rec said third by revenue showed XX%. old most one-time we as able from was that, recognition. we apples-to-apples revenue being quarter, the especially those gross think we we in quarter XXXX, the in with accrual-based moved disclosed that we the prior an without instruction, to third – discussed recognition quarter approximately adjustments, on from

The XXXX, than now XX%. we anything it's it mix that XX% effect about to So, show more XX% was will a estimate, else.

Switzerland. call, the net will from, also that a decision on national reimbursement So, we've talked on been for instance, on. We're where But But working it proving has improved hard through earlier to the about and significant Israel Medicare we the we're are things said be collection and impact as very like substantially during working that. we Germany, now. gross

Difei Yang

Okay, got it. Thank you.

accounting cash-based done? just been conversion So, quick a method the follow-up. basically to has say from completed accrual or Would you

Wilco Groenhuysen

there's reason that eliminates That's Yes, XXX accounting essentially well. XX/XX/XX applicable as and we out a that it's referenced adjustments for also cash that instruction accrual new forward. mere of going to been as completed the

Difei Yang

question Okay. side. scientific And then, on the another quick

either So, or do other GBM less complications? see you same you from the other, to to when move of or we see when more parts one complications we side move from do

Eilon Kirson

question. I'll that take Eilon. This is

We different mechanism parts expectation it the the the cell with Tumor – we basic action the is treated any because to We types all So, somewhat it's the of we types body, in that in Fields different we've other of we've see ubiquitous. Treating also in which future of advantage tumor pretty don't can in our is way, be, expect pre-clinically. the today. experience think ones based treated on mechanism our

And not expecting so, difference we're any the mechanism. in

discovered safety, always the or there possibility that in there's clinical be toxicities will Regarding toxicities, testing. new possible

However, not that date. to seen we have

have the Phase our pancreas, pilot to seen date. systemic studies, we in haven't of II seen in it not any toxicities in any mesothelioma studies ovarian, We

so, And therapy. we're the in the not change profile of expecting any risk-benefit

Difei Yang

field. the of a thank in the location the geographic factor the And on TT field? it's in follow-up is important quick maybe just all. a at then, Okay, tumor How location Or not you. that

Eilon Kirson

we definitely It which it a of within simulate the distributions wherever why the tumor, intensity order in and the body. in location, the field factor, is to optimize is fields plan is the

which You software optimize on a the patient. array is each for remember the that we them which physicians head, the glioblastoma, used to for to locations have plan planning therapy allows by

Difei Yang

Okay, thank you for the explanation.

Operator

Instructions]. [Operator

next Our with J.P. from comes question Kasimov Morgan. Cory

begin. may You

Shawn Fu

for year. Thanks And progress Cory. congrats on my for on question. Shawn is This taking the guys. this Hey,

X cohort from chance trial? [indiscernible] the that journals to is the PANOVA the from providing data will guys point? And INNOVATE. we've data Just see and Just some updated maybe from either PANOVA be them since X INNOVATE at thinking, those to X yet in plan you publish any wondering, or or

Eilon Kirson

not on data updating INNOVATE. planning we're the PANOVA or X So, from

of We in process in peer-reviewed published the are getting data the journals.

Shawn Fu

will some revenues geography? some by patients and at to continue point active point, your and break to just and ex-US pickup at US as your your ex-US, as to begin you maybe ramp opposed sales prescriptions And Okay. out

Asaf Danziger

do, Shawn. we I already think

disclosure, even are patients. break question active EMEA So, we we way down the break section. think have We we Germany on, section I in Maybe out where and is of that's whether disclosure, further European ahead later the now.

I any we to the currently, if happy talk think way the that aspects questions. have disclose about of our you business. comfortable we to with feel But you So, geographic

Shawn Fu

Okay, great. for And last question me.

order As online, with what further you you I consider various in or what reimbursement guess be would other come you these more get prompt start online, as EU markets the in what experienced entering – to come locales the for would and would guys Europe? to markets impetus

William Doyle

about Our penetrate to but respect already is we're like expectation XXXX, this that year markets. very course, in of to other the think, focus about the new markets talked Switzerland we're be with We'll, to present. I set opportunistic in markets, is We've for which Japan. the We've talk we'd active Israel, and Austria.

commercial coming in focus go have US. And the year. in for Germany the is GBM long to that the way a We and

Shawn Fu

Okay. Great, guys. Thanks again.

Operator

you. Thank

Mike with question King comes next Securities. Our JMP from

begin. may You

Michael King

Thanks question. morning, for my taking Good guys.

I'm support to from First guideline just if expand that in is is other of interested concerned, publication might if previous hit a bit you types? peer-reviewed of in the particularly strategy data NCCN tumor could And as any might XXXX. able a questioner far the follow-up as for what literature upon adoption be

Eilon Kirson

NCCN as That's in believe know, the JAMA full are we Thanks. the JAMA question. just maybe you December; quality-of-life trial support results trial same Oncology. and year an excellent February, GBM already, should the the in which Right think, now, of I of factors the from data Xst actually, significant we guideline. rethinking Those published the in XX final

during exactly There this know the should of what will we year. Other not during are other be said, never trials. as Again, pilot significant likely data on year. always published a publication. addition, the Those this actually publishing, In and data data I any from indications. you see, this back-and-forth. pancreatic our guidelines our publications. ovarian in at can developed point, be will preclinical data sets NCCN I do driving the depend is There

Michael King

I clarity you have commercial other have know don't Japan. my But thanks of answered. for of revenue guys opportunity one patients lot And and/or been of there. opportunity And question terms for Optune. in either number then, Okay, that questions dimensionalized you a the if about for

a please. So, color us might if you on give little that

Asaf Danziger

you question. for your Thank Yeah.

cases fact centers So, numbers start in any hospitals And contract besides Japan, not GBM to cases, to of in is the order a about train besides, and we're actually that already working number XXX X,XXX we're guiding patients year. [indiscernible]. the we other

Michael King

you about there's that Would that might to be adoption? less favorable anything say more Optune culturally market or

William Doyle

fact be the We therapy are to I Japanese the approved without that too pleased a only of by very think we trial. as know, bridging requirement in certainly the as early. it's Japan we're, far

tremendous is of which successful approval Society business, and reimbursement from both of will Neuro-Oncology, the we support into learn have that's go. we exactly the that with regulatory we commercial were as translates course, the reason how the But approval. We Japanese the JSNO, and

Michael King

I adverse lot just a been fairly has asking I'm Yeah, Right. have because to even toxic population historically, of know, that therapies or effects. highly that – patient side

it. would guys. well-suited it So, market. seem All Optune right. Thanks, Appreciate to that is

William Doyle

Thanks very much.

Operator

at further like Thank for the showing call remarks. closing back you. turn to this I'd over time. management no questions to I'm

William Doyle

financially significant future business and worldwide. We across us advancing dilution. XXXX, the of our tumor Novocure. both to I'd interest and made progress our patients of significant the was it leverage their progress prospect back made like helping significant When three other GBM solid year in mentioned, pipeline we a And objectives. our again, in made GBM tremendous So, allow Wilco progress for without develop to in primary in I achieving as with over progress to our thank everyone pipeline look We cancers.

thank you all. So,

Operator

a for and day. this your have Thanks Ladies concludes gentlemen, today's conference. and wonderful participation

NovoCure Limited (NVCR) 22 Feb 182017 Q4 Earnings call transcript